Center For Mental Health Prof. Dr. Ivan Temkov Burgas EOOD — Clinical Trial Site

8 Registered trials

4 Currently recruiting

Organisation

Center For Mental Health Prof. Dr. Ivan Temkov Burgas EOOD

Location

Burgas, Bulgaria

Identifier

ORG-100050701

Address

Complex Lazur, Lake Park, 8001, Bulgaria

Departments

Center For Mental Health Prof. Dr. Ivan Temkov Burgas EOOD
Department for treatment for emergency psychiatric conditions
Department for Treatment of Emergency Psychiatric Conditions
Department for Treatment of Emergency Psychiatric Conditions - Psychiatry Level III

Clinical trials at this site (8)

Search interface

A Phase 2 Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with Schizophrenia (STAR-1) Pending

2025-524058-32-00 Schizophrenia 4
A Phase 3 Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520259-26-00 Mania or Mania with Mixed Features in Bipolar-I Disorde 5 2025-09-25
A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder Recruiting

2024-513302-56-00 Generalized Anxiety Disorder 4 2025-11-17
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520165-32-00 BP-I mania or mania with mixed features 5 2025-11-04
A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi… Recruiting

2023-509070-36-00 Major Depressive Disorder with Insomnia Symptoms 5 2025-03-18
A study to assess the efficacy and safety of lumateperone in patients with Bipolar Mania Ended

2024-513037-20-00 Bipolar I Disorder (Bipolar Mania) 5 2024-12-19
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a… Ended

2024-513104-34-00 Major Depressive Disorder 4 2024-11-25
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended

2024-511557-21-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-11-14